文献速递肝病消化道肿瘤与早癌

糖尿病与肝硬化:诊断与管理的当前概念

Diabetes and cirrhosis: Current concepts on diagnosis and management.
PubMed 文献 · Hepatology · 2023-01-13

综述阐述2型糖尿病与肝硬化的复杂关系,指出糖尿病增加肝硬化相关并发症(含肝细胞癌)及总体死亡率。建议对2型糖尿病患者尽早用FIB-4联合瞬时弹性成像筛查NAFLD相关纤维化/肝硬化;肝硬化患者应早期诊断糖尿病,但Child-Pugh B-C级者A1C不可靠。管理需多学科团队,并警惕低血糖风险。

要点

  • 2型糖尿病患者应尽早用FIB-4序贯瞬时弹性成像筛查NAFLD相关纤维化/肝硬化。
  • 肝硬化合并肝功能受损(Child-Pugh B-C)者以A1C诊断糖尿病可能漏诊,贫血可使检测不可靠。
  • 肝硬化患者低血糖风险高,失代偿期胰岛素是唯一治疗,管理需多学科团队并利用新型血糖监测设备。

核心结论

  • 糖尿病增加肝硬化相关并发症包括肝细胞癌及总体死亡率。
  • 肝硬化患者应早期诊断糖尿病以优化管理策略(营养目标与血糖目标)。
  • 管理取决于患者为代偿期还是失代偿期肝硬化,需多学科团队参与并利用新型血糖监测设备。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 2型糖尿病常与肝硬化共存,急性疾病、药物及其他情况深刻改变糖代谢。
  • NAFLD是慢性肝病的主要原因,两种疾病在NAFLD中密切相关。
  • 肝硬化合并肝功能受损(Child-Pugh B-C)者以A1C诊断糖尿病可能漏诊,贫血可使检测不可靠。
  • 失代偿期肝硬化胰岛素是唯一治疗,患者低血糖风险高。

关键数值与推荐

  • 2型糖尿病患者应尽早系统筛查NAFLD相关纤维化/肝硬化,先用FIB-4指数,若有条件再做瞬时弹性成像。
  • 肝硬化患者应早期诊断糖尿病以制定最佳管理策略(营养目标与血糖目标)。
  • 临床医生应熟悉糖尿病药物在晚期纤维化与代偿期肝硬化患者中的安全性与有效性。

临床怎么用

  • 2型糖尿病患者用FIB-4序贯瞬时弹性成像筛查NAFLD相关纤维化/肝硬化。
  • 肝硬化患者诊断糖尿病不能仅依赖A1C,尤其Child-Pugh B-C级者。
  • 管理应在多学科团队(营养师、肥胖管理团队、内分泌科医生、肝病科医生等)内进行,并利用新型血糖监测设备。
  • 根据患者为代偿期或失代偿期肝硬化制定管理方案,失代偿期胰岛素是唯一治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 2 diabetes mellitus is often associated with cirrhosis as comorbidities, acute illness, medications, and other conditions profoundly alter glucose metabolism. Both conditions are closely related in NAFLD, the leading cause of chronic liver disease, and given its rising burden worldwide, management of type 2 diabetes mellitus in cirrhosis will be an increasingly common dilemma. Having diabetes increases cirrhosis-related complications, including HCC as well as overall mortality. In the absence of effective treatments for cirrhosis, patients with type 2 diabetes mellitus should be systematically screened as early as possible for NAFLD-related fibrosis/cirrhosis using noninvasive tools, starting with a FIB-4 index followed by transient elastography, if available. In people with cirrhosis, an early diagnosis of diabetes is critical for an optimal management strategy (ie, nutritional goals, and glycemic targets). Diagnosis of diabetes may be missed if based on A1C in patients with cirrhosis and impaired liver function (Child-Pugh B-C) as anemia may turn the test unreliable. Clinicians must also become aware of their high risk of hypoglycemia, especially in decompensated cirrhosis where insulin is the only therapy. Care should be within multidisciplinary teams (nutritionists, obesity management teams, endocrinologists, hepatologists, and others) and take advantage of novel glucose-monitoring devices. Clinicians should become familiar with the safety and efficacy of diabetes medications for patients with advanced fibrosis and compensated cirrhosis. Management is conditioned by whether the patient has either compensated or decompensated cirrhosis. This review gives an update on the complex relationship between cirrhosis and type 2 diabetes mellitus, with a focus on its diagnosis and treatment, and highlights knowledge gaps and future directions.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Castera L, Cusi K. Diabetes and cirrhosis: Current concepts on diagnosis and management. Hepatology. 2023. PMID: 36631005. doi:10.1097/HEP.0000000000000263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。